Introducing the MARS Atlas™ platform, a new solution for small-scale rapid CAR-T cell manufacturing, optimized for point-of-care settings. This presentation introduces the MARS Atlas™ platform, a new solution for small-scale rapid CAR-T cell manufacturing, optimized for point-of-care settings.
Key features include:
- Streamlined Protocols: Rapid CAR-T production starting from T cell selection using nano-beads or micro-beads,
- Enhanced Efficiency: Reduced manufacturing time (2-3 days) compared to the conventional 15+ days, with no expansion required, leading to less T cell exhaustion and higher potency,
- Cost-Effectiveness: Potential for manufacturing cost under $15k, making it more accessible with a smaller starting sample size,
- Simplified Process: Integration of magnetic and acoustic cell enrichment, allowing direct processing from peripheral blood, leukopak, or PBMC.
The MARS Atlas™ platform promises making high-potency CAR-T cell therapies more efficient and affordable, addressing the need for accessible cancer treatments.
This material was presented by Liping Yu at the 2024 Cell & Gene Therapy Summit in Boston.
